P18-BE3CRC / iNtRON Bio - LARVOL DELTA

iNtRON confirms cancer-controlling effect of PHAGERIA drug candidate in the organoid model. (PRNewswire) - "iNtRON Biotechnology...announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate of PHAGERIA® platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) effective for cancer control."

Commercial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor